We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Childhood Hereditary Spherocytosis Confirmed by Hematology Analyzer

By LabMedica International staff writers
Posted on 25 Feb 2015
Print article
Image: The CELL-DYN Sapphire hematology analyzer (Photo courtesy of Abbott Diagnostics).
Image: The CELL-DYN Sapphire hematology analyzer (Photo courtesy of Abbott Diagnostics).
The hallmark of hereditary spherocytosis (HS) is a decreased surface area-to-volume ratio of the erythrocytes (RBC), resulting in the characteristic spherocyte form and in a blood film, spherocytes have a smaller diameter than normal RBC and are hyperchromic.


The flow cytometric eosin-5′-maleimide test (EMA) is highly sensitive and specific for HS as a confirmatory method and the utility of hyperchromic erythrocytes in HS screening and evaluation of the EMA test performed on a hematology analyzer was compared with the reference method.

Hematologists at Our Lady's Children's Hospital (Crumlin, Dublin, Ireland) analyzed blood samples from 740 pediatric patients presenting at their institution in the reticulocyte mode of the CELL-DYN Sapphire hematology analyzer (Abbott Diagnostics; Wiesbaden-Delkenheim, Germany) to obtain hyperchromic erythrocyte counts. The EMA test used as a reference for the laboratory diagnosis of HS was performed on a FACSCanto II flow cytometer (Becton Dickinson; San Jose, CA, USA).

Hyperchromic erythrocytes were the highest in patients with HS (median 11.5%; range 5.1 to 29.2%). Patients with autoimmune hemolytic disease had significantly less hyperchromic erythrocytes (median 4.9%; range 0.0 to 18.3%). Hyperchromic erythrocytes showed a high area under the receiver operating characteristic (ROC) curve of 0.972. At 4.9% cut-off, hyperchromic erythrocytes detected HS with 96.4% sensitivity and 99.1% specificity. The EMA test on CELL-DYN Sapphire correlated strongly with the reference test and had identical diagnostic power. Stability studies with blood from HS patients showed a significant decrease in hyperchromic erythrocytes after six hours of storage.

The authors concluded that measurement of hyperchromic erythrocytes is highly sensitive and specific for detecting HS and can be used for rapid and inexpensive screening. If required, the EMA test can be performed on the CELL-DYN Sapphire or a standard flow cytometer for confirmation of HS. The study was published in the February 2015 issue of the International Journal of Laboratory Hematology.

Related Links:

Our Lady's Children's Hospital 
Abbott Diagnostics 
Becton Dickinson


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
New
MTHFR Mutation Test
REALQUALITY THROMBO MTHFR
New
Automated Immunoassay Analyzer
Phadia 1000

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.